Evoke Pharma, Inc. (EVOK)

Evoke Pharma Statistics

Total Valuation

Evoke Pharma has a market cap or net worth of $11.54 million. The enterprise value is $4.61 million.

Market Cap	11.54M
Enterprise Value	4.61M

Important Dates

The last earnings date was Thursday, August 14, 2025, before market open.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Evoke Pharma has 2.09 million shares outstanding. The number of shares has increased by 295.97% in one year.

Current Share Class	1.56M
Shares Outstanding	2.09M
Shares Change (YoY)	+295.97%
Shares Change (QoQ)	+0.18%
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	4.52%
Float	1.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.15
Forward PS	1.26
PB Ratio	2.56
P/TBV Ratio	2.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.17.

Current Ratio	1.37
Quick Ratio	1.29
Debt / Equity	1.17
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.68

Financial Efficiency

Return on equity (ROE) is -152.92% and return on invested capital (ROIC) is -38.88%.

Return on Equity (ROE)	-152.92%
Return on Assets (ROA)	-23.67%
Return on Invested Capital (ROIC)	-38.88%
Return on Capital Employed (ROCE)	-120.28%
Revenue Per Employee	$4.26M
Profits Per Employee	-$1.79M
Employee Count	3
Asset Turnover	0.91
Inventory Turnover	0.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.79% in the last 52 weeks. The beta is -0.04, so Evoke Pharma's price volatility has been lower than the market average.

Beta (5Y)	-0.04
52-Week Price Change	+13.79%
50-Day Moving Average	4.32
200-Day Moving Average	4.02
Relative Strength Index (RSI)	54.74
Average Volume (20 Days)	477,491

Short Selling Information

The latest short interest is 52,728, so 2.53% of the outstanding shares have been sold short.

Short Interest	52,728
Short Previous Month	241,722
Short % of Shares Out	2.53%
Short % of Float	3.79%
Short Ratio (days to cover)	0.01

Income Statement

In the last 12 months, Evoke Pharma had revenue of $12.79 million and -$5.38 million in losses. Loss per share was -$2.03.

Revenue	12.79M
Gross Profit	12.36M
Operating Income	-5.34M
Pretax Income	-7.13M
Net Income	-5.38M
EBITDA	n/a
EBIT	-5.34M
Loss Per Share	-$2.03

Balance Sheet

The company has $12.06 million in cash and $5.13 million in debt, giving a net cash position of $6.93 million or $3.32 per share.

Cash & Cash Equivalents	12.06M
Total Debt	5.13M
Net Cash	6.93M
Net Cash Per Share	$3.32
Equity (Book Value)	4.37M
Book Value Per Share	2.16
Working Capital	4.31M

Cash Flow

Operating Cash Flow	-3.62M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 96.63%, with operating and profit margins of -41.74% and -42.07%.

Gross Margin	96.63%
Operating Margin	-41.74%
Pretax Margin	-42.07%
Profit Margin	-42.07%
EBITDA Margin	n/a
EBIT Margin	-41.74%
FCF Margin	n/a

Dividends & Yields

Evoke Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-295.97%
Shareholder Yield	-295.97%
Earnings Yield	-46.63%
FCF Yield	n/a

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 1, 2024. It was a reverse split with a ratio of 1:12.

Last Split Date	Aug 1, 2024
Split Type	Reverse
Split Ratio	1:12

Scores

Evoke Pharma has an Altman Z-Score of -11.06 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.06
Piotroski F-Score	3